For years, public discussions about kratom have often reduced a chemically complex plant to one or two names: mitragynine and 7-hydroxymitragynine, commonly called 7-OH.
A newly published study shows why that simplified picture is incomplete.
On August 17, 2026, researchers from the University of Florida and Johns Hopkins University published a study in Pharmaceutical Biology titled “Simultaneous quantification of seventeen kratom alkaloids and metabolites in human plasma and its application to clinical pharmacokinetic sample analysis”.
The researchers developed a laboratory method capable of measuring 12 kratom alkaloids and five mitragynine metabolites in human plasma at the same time. They then applied the method to blood samples collected from four adults who regularly consumed kratom.
The takeaway is not that this study proves kratom is completely safe or effective. It did not attempt to do that. Its real contribution is analytical: researchers can now see much more of kratom’s chemical picture in human blood.
That matters for clinical research, product science, pharmacokinetics and forensic toxicology. It also matters whenever someone claims that finding 7-OH or mitragynine pseudoindoxyl in blood automatically proves that a concentrated or chemically enhanced product was consumed.
The science is more complicated than that.
What Was the Purpose of the Study?
This was primarily a laboratory-method and pharmacokinetic study, not a safety trial or a test of kratom’s medical effectiveness.
The researchers developed and validated a UPLC-MS/MS method. In plain English, this is a highly sensitive laboratory system that separates compounds in a biological sample and identifies them according to their molecular characteristics.
Previous blood-testing methods generally focused on mitragynine, 7-OH or a small number of major alkaloids. This new method measured a much broader group:
- Mitragynine
- Speciogynine
- Speciociliatine
- Mitraciliatine
- Paynantheine
- Isopaynantheine
- Corynantheidine
- Corynoxine A
- Corynoxine B
- Mitraphylline
- Speciofoline
- Ajmalicine
It also measured five mitragynine-related metabolites:
- 7-hydroxymitragynine, or 7-OH
- Mitragynine pseudoindoxyl
- Mitragynine 16-carboxylic acid
- 9-hydroxycorynantheidine
- 3-dehydromitragynine
Think of it this way: earlier testing often recorded only the lead instrument. This method allows researchers to hear considerably more of the entire band.
How Was the Human Portion Conducted?
The researchers analyzed plasma from four healthy adults enrolled in an ongoing Johns Hopkins direct-observation study of regular kratom consumers.
To qualify for the broader study, participants had to be at least 21 years old and report taking kratom at least five days per week for at least three months. The four participants included in this paper took one self-selected serving of the commercial product they normally used:
- 2.7 grams of Super Green kratom powder
- 5.3 grams of Red Maeng Da kratom powder
- 7.4 grams of Green Maeng Da kratom powder
- 15 milliliters of a MIT-45 Super-K liquid shot
Blood samples were collected before dosing and at multiple points during the following 24 hours.
The three powders and one liquid product were chemically analyzed. According to the researchers, their alkaloid patterns were similar to typical Mitragyna speciosa leaf material, although the liquid product was an extract and differed in formulation.
The individual products delivered approximately 26.6 to 54.1 milligrams of mitragynine and approximately 0.2 to 0.9 milligrams of 7-OH.
Most Kratom Alkaloids Were Absorbed Quickly
Most measured alkaloids reached their maximum plasma concentration within one to two hours after consumption.
There were several exceptions. Mitragynine pseudoindoxyl peaked at three hours in one participant. Mitraciliatine peaked at 3.5 hours in another, and corynoxine B peaked later in one participant.
This general one-to-two-hour window provides useful information about how quickly kratom alkaloids become systemically available after oral consumption. However, the study involved only four regular consumers using different products and doses. It should not be treated as a universal timeline for every person or every formulation.
Several Alkaloids Remained in Plasma for Many Hours
The researchers reported long and variable half-lives for several alkaloids:
- Mitragynine: 17.1 to 35.1 hours
- Speciogynine: 10.2 to 32.1 hours
- Speciociliatine: 9.8 to 23.7 hours
- Mitraciliatine: 24.3 to 63.2 hours
- Paynantheine: 10.3 to 27.7 hours
- Isopaynantheine: 14.9 to 33.3 hours
A half-life is the estimated time required for the plasma concentration of a compound to fall by half. It does not mean the compound is completely eliminated after one half-life.
Because these participants were regular consumers, several alkaloids and metabolites were already measurable before the supervised dose. They had stopped consuming kratom after midnight, but that was not enough time to clear compounds that may remain in circulation for a day or longer.
This helps explain why repeated daily consumption can produce persistent baseline concentrations. Pharmacokinetic accumulation means that some amount remains when the next serving is taken. It does not, by itself, establish impairment, intoxication or toxicity.
Mitragynine Was Not the Only Important Circulating Alkaloid
Mitragynine was the most abundant alkaloid in the products, but the blood results showed that it was not acting alone.
Speciociliatine, mitraciliatine and isopaynantheine produced relatively high dose-normalized exposure. In other words, compared with the amount consumed, these compounds appeared to enter or remain in circulation efficiently.
That does not mean they produced stronger clinical effects than mitragynine. Plasma exposure is only one part of pharmacology. Receptor activity, distribution, metabolism and interactions among compounds also matter.
The finding nevertheless reinforces an important point: natural kratom is a multi-alkaloid botanical. Its chemistry cannot be accurately represented by treating mitragynine or 7-OH as the entire plant.
For more background, read our guide to alkaloids in kratom.
The Bottom Line
The 2026 study does not settle every question about kratom. It gives researchers a better way to ask those questions.
Its most defensible conclusions are straightforward:
- Kratom is pharmacologically more complex than mitragynine alone.
- 7-OH is not the largest circulating mitragynine metabolite identified in this small study.
- 7-OH and pseudoindoxyl can be detected after ordinary commercial kratom products are consumed.
- Their presence alone cannot prove direct use of a concentrated 7-OH or pseudoindoxyl product.
- Accurate interpretation requires concentrations, ratios, a complete alkaloid profile and proper sample handling.
Natural occurrence does not make concentration irrelevant. At the same time, the presence of a naturally produced metabolite should not be misrepresented as proof of direct exposure to a chemically enhanced product.
Facts over fear means following the evidence in both directions.
